Search
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalMost recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881] … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.
Products: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mgCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Synonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochlorideProducts: REAGİLA 6 MG SERT KAPSÜL, 30 ADET, REAGİLA 3 MG SERT KAPSÜL, 30 ADETTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Products: Tositin 10 mg Film Kaplı Tablet, 56 ADET, JANTY 5 MG FİLM KAPLI TABLET, 56 ADETCabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline possesses potent agonist activity on dopamine D2 receptors. … Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.
Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamideProducts: DOSTINEX 0,5 MG TABLET, 8 ADET, CABASER 1 MG TABLET, 20 ADETRoxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigational[A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323] … Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease.
Products: Ernevod 20 mg Film Kaplı Tablet (12 adet), Ernevod 50 mg Film Kaplı Tablet (12 adet)Buspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigational[A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®. … [L7375] The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated.[A181751]
Synonyms: 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dioneProducts: BUSPON 10 MG KAPSÜL, 50 KAPSÜL, NOPIRON 10 MG TABLET, 50 ADETRemdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues.
Products: VEKLURY 100 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADETFamciclovir
go.drugbank.com/drugs/DB00426ApprovedInvestigationalFamciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Products: FAMVIR (250 MG ), FAMVIR 125 MG TABLETASBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigational[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM).
Products: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MGLisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal
Products: SAMEXID 70 MG, VYVANSE CAPSULES 20 mg